First right lobe living-donor hepatectomy after sleeve gastrectomy

Obed, Aiman; Bashir, Abdalla; Jarrad, Anwar

doi:10.1186/s12893-018-0366-7

Cited by 7 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though the idea is still in its infancy, there have been reports of donor hepatectomy after bariatric surgery, which leads to loss of weight and improved steatosis leading to donor hepatectomy [43][44][45].…”

Section: Bariatric Surgerymentioning

confidence: 99%

Management of Steatosis in Living Donors: Where Do We Stand?

Chaudhary,

Gupta,

Jamir

et al. 2024

OBM Transplant

View full text Add to dashboard Cite

With the progressive rise in rates of liver transplantation, stagnant donor pool, and social factors, living donor liver transplantation (LDLT) forms the majority of liver transplantations performed in Asian countries. As the global prevalence of metabolic-associated fatty liver disease (MAFLD) is increasing, around 17-25% of all the prospective donors turn out to be steatotic at the time of evaluation and, as such, rejected for donor hepatectomy, thereby considerably reducing the living donor pool. Steatotic grafts are a risk factor to both the recipient (primary nonfunction, delayed graft function, and mortality) and the donor (poor regeneration, higher blood loss, and prolonged hospital stay). Weight reduction and dietary optimization have been known to be associated with improvement in steatosis, and multiple interventions have been used in the past to reduce steatosis in these donors and be able to convert these donors from marginal steatotic donors to normal or low-risk donors and utilize these grafts. Most of these studies indicated the efficacy of these optimization protocols. They suggested similar outcomes in these previously steatotic donors compared to donors without steatosis at baseline, but these optimization protocols lack uniformity. This review article aims to highlight the rising prevalence of steatosis in living liver donors, assess the literature on pre-operative management options for steatosis donors, and study the efficacy, safety, and feasibility of these management options.

show abstract

Section: Bariatric Surgerymentioning

confidence: 99%

Management of Steatosis in Living Donors: Where Do We Stand?

Chaudhary,

Gupta,

Jamir

et al. 2024

OBM Transplant

View full text Add to dashboard Cite

show abstract

“…Although minimal adhesions were found intraoperatively, no complications and normal liver function were reported at 8 months follow-up. [ 47 ] Another case series reported right-lobe liver donation in 4 patients with a history of bariatric surgery for weight loss. In these select donors with no comorbidity, pre-transplant steatosis was evaluated by MRI-PPF and ranged from 0.1% to 3.3%.…”

Section: Pre-transplant Bmi Optimizationmentioning

confidence: 99%

Practice patterns and considerations in liver transplantation from living donors with high BMI: A review

Samaha

2023

Hepatology Forum

View full text Add to dashboard Cite

Living Donor Liver Transplantation (LDLT) is a valuable solution to the shortage of donor organs for patients with end-stage liver disease. However, the eligibility of obese donors for LDLT remains a subject of debate. This literature review explores global practices and perceptions of LDLT, identifies donor eligibility criteria, and discusses special considerations and ethical caveats. The review highlights the need for standardized guidelines for donor selection, considering the global distribution of Body mass index and variations in population-specific criteria. It also emphasizes the importance of non-invasive testing and pre-operative optimization of liver steatosis for select obese donors. Furthermore, the review examines the outcomes and complications associated with obese donors in LDLT. The findings of this review contribute to the ongoing discussion on the inclusion of obese donors in LDLT and provide insights for future research and guideline development.

show abstract

“…A remedy for steatotic livers in living donor candidates will also increase the organ pool. Indeed, the first successful case of a right lobe living donor hepatectomy in a patient who previously underwent bariatric surgery for obesity was recently published …”

Section: Nafld a Common Disease Affecting The Use Of Steatotic Graftmentioning

confidence: 99%

“…Indeed, the first successful case of a right lobe living donor hepatectomy in a patient who previously underwent bariatric surgery for obesity was recently published. (15) On the other hand, in our view, further research is required to select drugs that can regulate hepatic fatty infiltration with minimal adverse effects and to optimize such potential treatments (ie, dose and pharmacokinetics) before being translated into treatments for human disease. In our opinion, drugs or surgical procedures that reduce hepatic steatosis should be considered with caution in clinical liver surgery due to the potential adverse effects of these drugs or the Review ARticle | 773 potential risk associated with bariatric surgery.…”

Section: Nafld a Common Disease Affecting The Use Of Steatotic Graftmentioning

confidence: 99%

Use of Steatotic Grafts in Liver Transplantation: Current Status

et al. 2019

View full text Add to dashboard Cite

In the field of liver transplantation, the demand for adequate allografts greatly exceeds the supply. Therefore, expanding the donor pool to match the growing demand is mandatory. The present review summarizes current knowledge of the pathophysiology of ischemia/reperfusion injury in steatotic grafts, together with recent pharmacological approaches aimed at maximizing the utilization of these livers for transplantation. We also describe the preclinical models currently available to understand the molecular mechanisms controlling graft viability in this specific type of donor, critically discussing the heterogeneity in animal models, surgical methodology, and therapeutic interventions. This lack of common approaches and interventions makes it difficult to establish the pathways involved and the relevance of isolated discoveries, as well as their transferability to clinical practice. Finally, we discuss how new therapeutic strategies developed from experimental studies are promising but that further studies are warranted to translate them to the bedside.

show abstract

First right lobe living-donor hepatectomy after sleeve gastrectomy

Cited by 7 publications

References 22 publications

Management of Steatosis in Living Donors: Where Do We Stand?

Management of Steatosis in Living Donors: Where Do We Stand?

Practice patterns and considerations in liver transplantation from living donors with high BMI: A review

Use of Steatotic Grafts in Liver Transplantation: Current Status

Contact Info

Product

Resources

About